Middle East respiratory syndrome coronavirus (MERS-CoV) is a stage 3 zoonosis that has been reported in 26 countries, including the United States ([@KWW013C1], [@KWW013C2]). The virus was first recognized in Saudi Arabia in 2012, though it may have been circulating in the region much longer ([@KWW013C3], [@KWW013C4]). As of August 18, 2015, there have been 1,413 confirmed cases and 502 deaths ([@KWW013C5]). The virus causes severe respiratory illness in humans and has a mortality rate of 30%--40% ([@KWW013C6]). Treatment for MERS-CoV cases is limited to supportive care.

Certain groups may be at higher risk of contracting the virus or of having their cases ascertained due to illness severity, including males and those with comorbid medical conditions, such as diabetes and heart disease. Common symptoms include fever, cough, shortness of breath, chest pain, and diarrhea ([@KWW013C7], [@KWW013C8]). The virus is probably transmitted from camels to humans, and stuttering chains (groups of cases linked by a continuous chain of transmission events that arise periodically) of human-to-human transmission are also possible ([@KWW013C4], [@KWW013C7]). Human-to-human transmission occurs between 2 people in close contact, a circumstance common in households and health-care settings. Early identification and isolation of cases is critical for limiting spread of the virus.

Information on the epidemiology of MERS-CoV has been limited to date. Prior work on the 2013 influenza (A)H7N9 outbreak found that line listings of cases aggregated from publicly available sources like media and public health reports compare favorably to official line listings ([@KWW013C11]). These public line listings can be used to gain insight into an ongoing outbreak in a timely manner, as official data tend to be released only after outbreaks are over. Real-time analyses are vital to planning and implementing effective public health control measures to prevent the spread of the disease. We used publicly available data to evaluate the risks of death and severe disease among patients with MERS-CoV.

METHODS {#s2}
=======

Data sources {#s2a}
------------

A publicly accessible line listing of MERS-CoV cases, maintained by Dr. Andrew Rambaut and available online ([@KWW013C12]), was accessed on August 4, 2015. This line listing contained 1,291 cases of MERS-CoV infection pulled from a number of sources, including the World Health Organization and the government of the Kingdom of Saudi Arabia. This data set has often been more up-to-date than official World Health Organization case reports, especially early in the epidemic. The outcomes available are as reported and do not necessarily reflect the final status of the patient after prolonged follow-up, so some misclassification of outcomes is possible. The majority of MERS-CoV cases occurred in Saudi Arabia, South Korea, and the United Arab Emirates (Appendix Table [1](#KWW013TB3){ref-type="table"}). The outbreak in South Korea was excluded from the analysis because of its unique nature, resulting in 1,105 cases after exclusion.

Exposure definition and covariate selection {#s2b}
-------------------------------------------

Outcomes of interest were death and severe disease. The status of the patient as either alive or deceased was determined by whether or not the patient had died at the time of initial reporting. Patients with severe disease were considered those who had either died from their infection or required critical care at the time of initial reporting, as opposed to those who experienced few or less serious complications.

Risk factors considered were the patient\'s age, the date of onset of the infection, the presence or absence of any underlying comorbidity such as cardiac or renal disease, reported contact with camels or other animals, whether or not the patient was employed as a health-care worker, whether or not the case was a primary or secondary case (based on reported contact with an existing case), whether or not the case arose in Saudi Arabia (the nation in which the majority of cases originated), the patient\'s sex, the number of days since January 1, 2012, and the time between onset of infection and subsequent hospitalization.

Missing data {#s2c}
------------

Because of the emerging nature of the disease, the widely varying sources from which the case reports were drawn, difficulty in case ascertainment, and sparse reporting, the data set used (12) had extensively missing data. There were 920 cases with missing information on 1 or more variables (including outcome variables), making conventional complete-case analysis essentially impossible. Because there was no evidence that these cases were missing data completely at random, estimates could be biased.

We used a bootstrap-based expectation maximization method to multiply impute the missing information ([@KWW013C13]). One hundred imputations were used, based on the assumption that all data for the variables included in the analysis, missing or observed, came from a multivariate normal distribution. A ridge prior of 1% of the empirical data was used to assist with the numerical stability of the algorithm. The ridge prior in essence adds an additional number of observations equal to 1% of the data set with the same mean and variance as the observed data, but with no covariance. This shrinks the covariance between the variables in the imputation model and assists the algorithm in converging on a stable solution, which is sometimes necessary with high degrees of missingness, as in this case. Priors using 0.5% of the data or 2% of the data did not result in meaningful differences in the results (not shown).

Regression models {#s2d}
-----------------

Poisson regression models using a robust variance estimator ([@KWW013C14]) were used to estimate the univariate relative risk of either outcome according to each potential risk factor. These models are comparable to those obtained using binomial regression, though often more computationally tractable. Those variables that were moderately associated (*P* \< 0.20) with the outcome were included in a multivariate risk model. All analysis was performed with the R statistical programming language (R Foundation for Statistical Computing, Vienna, Austria) using the `Amelia2` package for multiple imputation ([@KWW013C15]).

Human subjects approval {#s2e}
-----------------------

Because this work used entirely publicly available information with no personal identifiers, it was determined to not require approval by an institutional review board.

RESULTS {#s3}
=======

Demographic characteristics {#s3a}
---------------------------

The distribution of patient ages for both fatal and nonfatal cases is shown in Figure [1](#KWW013F1){ref-type="fig"}. The distributions of other variables, including the numbers of missing values, are reported in Table [1](#KWW013TB1){ref-type="table"}.

###### 

Demographic and Risk Factor Characteristics of Patients With Reported Middle East Respiratory Syndrome Coronavirus Infection, 2012--2015

  Variable                                     All Patients   Severe Cases                              
  -------------------------------------------- -------------- -------------- ------------- ----- ------ -------------
  Age, years                                                                 50 (18)                    57 (17)
   Missing data                                11             1.0                          11    2.1    
  Time of onset (days since January 1, 2012)                                 911 (255)                  881 (277)
   Missing data                                461            41.7                         163   31.8   
  Underlying comorbidity                                                                                
   Yes                                         565            51.1                         361   70.4   
   No                                          526            47.6                         143   27.9   
   Missing data                                14             1.3                          9     1.8    
  Reported animal contact                                                                               
   Yes                                         105            9.5                          53    10.3   
   No                                          278            25.2                         146   28.5   
   Missing data                                722            65.3                         314   61.2   
  Reported camel contact                                                                                
   Yes                                         84             7.6                          41    8.0    
   No                                          233            21.1                         117   22.8   
   Missing data                                788            71.3                         355   69.2   
  Health-care worker                                                                                    
   Yes                                         168            15.2                         38    7.4    
   No                                          351            31.8                         189   36.8   
   Missing data                                586            53.0                         286   55.8   
  Case type                                                                                             
   Primary                                     216            19.5                         130   25.3   
   Secondary                                   484            43.8                         151   29.4   
   Missing data                                405            36.7                         232   45.2   
  Case origin                                                                                           
   Saudi Arabia                                959            86.8                         457   89.1   
   Other country                               146            13.2                         56    10.9   
   Missing data                                                                                         
  Sex                                                                                                   
   Male                                        736            66.6                         370   72.1   
   Female                                      346            31.3                         132   25.7   
   Missing data                                23             2.1                          11    2.1    
  Delay in hospitalization, days                                             4.91 (4.41)                3.80 (4.39)
   Missing data                                577            52.2                         216   42.1   

Abbreviation: SD, standard deviation.

![Gaussian kernel-smoothed age distributions of fatal and nonfatal cases of Middle East respiratory syndrome coronavirus from 2012 to 2015.](kww01301){#KWW013F1}

Risk factors for reported mortality {#s3b}
-----------------------------------

The estimated relative risk of death and corresponding 95% confidence intervals for the covariates described in the Methods section are shown in Table [2](#KWW013TB2){ref-type="table"}. As with any emerging infection, both the presence and the absence of associations with putative risk factors warrant reporting. Univariate analysis showed that reported contact with camels or other animals, cases occurring in Saudi Arabia, and case type (a case\'s being primary vs. secondary) were not associated with reported mortality. Employment as a health-care worker and an increased amount of time between disease onset and hospitalization had minor protective associations with reported mortality. Older age and underlying comorbidity were associated with increased risks of mortality, while female patients and cases with a later time of infection onset (in days since January 1, 2012) had lower risks of mortality. Upon multivariate adjustment, most of the estimated associations were attenuated, and neither female sex nor time between disease onset and hospitalization remained an independent risk factor.

###### 

Estimated Relative Risks of Death and Severe Disease at the Time of Reporting for Patients With Middle East Respiratory Syndrome Coronavirus, 2012--2015

  Variable                   Death   Severe Disease                                                  
  -------------------------- ------- ---------------- ------ ------------ ------ ------------ ------ ------------
  Age                        1.02    1.02, 1.03       1.01   1.00, 1.02   1.02   1.02, 1.02   1.01   1.01, 1.01
  Time of onset^c^           1.00    1.00, 1.00       1.00   1.00, 1.00   1.00   1.00, 1.00   1.00   1.00, 1.00
  Underlying comorbidity     2.51    1.87, 3.37       1.99   1.39, 2.86   2.23   1.93, 2.46   1.65   1.39, 1.97
  Animal contact             1.16    0.74, 1.80                           1.10   0.89, 1.35          
  Camel contact              1.19    0.73, 1.93                           1.10   0.89, 1.37          
  Health-care worker         0.52    0.33, 0.81       0.46   0.28, 0.75   0.49   040, 0.60    0.61   0.48, 0.79
  Secondary case             0.84    0.60, 1.18                           0.60   0.52, 0.70   0.82   0.69, 0.97
  Saudi Arabia               0.85    0.60, 1.21                           1.18   0.95, 1.45   1.24   1.02, 1.52
  Female sex                 0.75    0.56, 1.00       0.93   0.70, 1.25   0.77   0.66, 0.89   0.92   0.81, 1.06
  Hospitalization delay^d^   0.85    0.81, 0.89       0.99   0.95.1.03    0.99   0.97, 1.01          

Abbreviations: aRR, adjusted relative risk; CI, confidence interval; RR, relative risk.

^a^ Multivariate model that adjusted for age, presence of comorbidity, reported contact with animals, health-care worker status, case type (primary vs. secondary), and patient sex.

^b^ Multivariate model that adjusted for age, time of onset, presence of comorbidity, health-care worker status, case type (primary vs. secondary), and patient sex.

^c^ Days since January 1, 2012.

^d^ Reported number of days between onset and subsequent hospitalization.

Risk factors for reported severe disease {#s3c}
----------------------------------------

The estimated relative risks of severe disease and corresponding 95% confidence intervals are shown in Table [2](#KWW013TB2){ref-type="table"}. Reported contact with camels or other animals, regardless of whether or not the case arose in Saudi Arabia, and longer delays between disease onset and hospitalization were not associated with an increased risk of severe disease. Increased age and the presence of underlying comorbidity were associated with an increased risk of severe disease. Female sex, having a secondary case, having a case arising later in time, and employment as a health-care worker were protective against severe disease.

As with the risk of reported death, the multivariate associations were largely attenuated from the univariate associations, and notably, female sex was no longer protective once other variables had been controlled for. As compared with the risk of death, the estimated associations for severe disease were frequently closer to the null.

DISCUSSION {#s4}
==========

The emergence of a novel infectious disease presents a particular challenge to timely epidemiologic research, as the existence of sparse and irregularly collected data competes with the need to identify risk factors associated with the disease and its outcomes. A dearth of openly shared data impedes research efforts, such as the construction of mathematical models or broader-scale risk assessments. We have attempted to address this for MERS-CoV, using a regularly updated, publicly available data set. The use of multivariate models with allowance for extensively missing data has allowed the identification of some previously suggested risk factors that do not appear to be so upon adjustment for other covariates. For example, female patients were not necessarily at lower risk for disease after adjustment, nor were primary cases at higher risk for fatal infections. Issues of data quality and "missingness" during outbreaks necessitate the use of robust techniques for handling missing data.

We found that older age and underlying comorbidity were associated with increased risks of both death and severe disease. While not a surprising finding, this does suggest that older and sicker patients merit heightened vigilance. Additionally, cases arising progressively later during the epidemic have been associated with lower risks of both death and severe disease at the time of initial reporting, suggesting that treatment methods for MERS-CoV may be increasing in efficacy. Alternately, the proportion of mild and asymptomatic cases has been rising over time, suggesting that less severe cases are becoming more likely to be ascertained as a result of epidemiologic investigation. This is supported by temporal trends in the missingness of the data, which grows less severe later in the epidemic.

This study was not without limitations, especially those stemming from the data used. Patient outcomes were identified at the time of reporting, rather than based on follow-up, so it is possible that some patients counted as living or without severe disease may have experienced serious or fatal complications after reporting, which would not have been recorded in the data. There is also the possibility of unmeasured confounding biasing these estimates or the multiple imputation model not fully addressing the missingness within the data set. These issues are unlikely to be resolved without more resource-intensive population-based studies.

Despite these shortcomings, the study represents an attempt to quantify the known risk factors for MERS-CoV using the best available and open data. While the estimates are imperfect, they are superior to univariate associations that do not control for confounding, or allowing paralysis in the face of difficult and imperfect data to deprive public health planners of potentially useful information. These estimates can and should be revised as more becomes known about the disease, but for the moment, they represent the current state of our knowledge about MERS-CoV and its impact on human health outcomes.
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###### 

Locations of known cases of Middle East respiratory syndrome coronavirus as of August 4, 2015^a^

  Country                   No. of Cases   
  ------------------------- -----------------
     France                 1   
     Iran                   8   
     Italy                  2   
     Jordan                 20   
     Saudi Arabia           959   
     Kuwait                 3   
     Lebanon                1   
     Omar                   9   
     Qatar                  15   
     South Korea            186^b^   
     Tunisia                2   
     United Arab Emirates   77   
     United Kingdom         2   
     Yemen                  1   
     Missing                5   
     Total                  1,291   

^a^ Data were obtained from a publicly accessible line listing of cases maintained by Dr. Andrew Rambaut ([@KWW013C12]).

^b^ Cases from South Korea were excluded from the current analysis.

[^1]: Abbreviation: MERS-CoV, Middle East respiratory syndrome coronavirus.
